Rallybio Co. (NASDAQ:RLYB) Receives $12.20 Consensus PT from Brokerages

Rallybio Co. (NASDAQ:RLYB) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $12.20.

Several equities analysts recently commented on the company. Jefferies Financial Group cut Rallybio from a “buy” rating to a “hold” rating in a research report on Wednesday, February 7th. JMP Securities restated a “market outperform” rating and set a $8.00 target price on shares of Rallybio in a research report on Thursday, April 18th. HC Wainwright cut their price objective on Rallybio from $12.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. Finally, Wedbush cut their price objective on Rallybio from $13.00 to $11.00 and set an “outperform” rating for the company in a report on Thursday, April 11th.

Rallybio Stock Performance

NASDAQ:RLYB opened at $1.58 on Monday. Rallybio has a 52-week low of $1.23 and a 52-week high of $9.14. The firm has a market cap of $59.74 million, a price-to-earnings ratio of -0.86 and a beta of -1.64. The business’s fifty day moving average is $1.81 and its 200 day moving average is $2.28.

Rallybio (NASDAQ:RLYB) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Equities analysts predict that Rallybio will post -1.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Rallybio

Several institutional investors have recently bought and sold shares of RLYB. SG Americas Securities LLC purchased a new stake in Rallybio during the 4th quarter valued at about $40,000. Financial Security Advisor Inc. purchased a new stake in Rallybio during the 3rd quarter valued at about $169,000. Finally, abrdn plc purchased a new stake in Rallybio during the 4th quarter valued at about $4,128,000. 90.34% of the stock is currently owned by hedge funds and other institutional investors.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.